Bioventus Inc. BVS
NASDAQ
| 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 581.85M | 576.30M | 568.09M | 563.83M | 564.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 581.85M | 576.30M | 568.09M | 563.83M | 564.14M |
| Cost of Revenue | 182.40M | 180.43M | 179.93M | 181.80M | 182.79M |
| Gross Profit | 399.45M | 395.87M | 388.16M | 382.03M | 381.35M |
| SG&A Expenses | 322.42M | 318.80M | 313.98M | 318.01M | 320.80M |
| Depreciation & Amortization | 4.84M | 5.24M | 5.73M | 6.20M | 6.87M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 521.24M | 516.04M | 511.75M | 518.38M | 523.75M |
| Operating Income | 60.61M | 60.26M | 56.34M | 45.45M | 40.39M |
| Income Before Tax | 38.64M | 33.64M | 25.71M | 11.51M | 1.58M |
| Income Tax Expenses | -22.84M | -899.00K | -1.57M | 2.16M | 2.09M |
| Earnings from Continuing Operations | 61.48 | 34.54 | 27.27 | 9.35 | -0.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -7.01M | -6.06M | -4.54M | -1.76M | -230.00K |
| Net Income | 54.46M | 28.48M | 22.73M | 7.59M | -731.00K |
| EBIT | 60.61M | 60.26M | 56.34M | 45.45M | 40.39M |
| EBITDA | 99.49M | 100.24M | 96.98M | 85.55M | 81.37M |
| EPS Basic | 0.81 | 0.43 | 0.34 | 0.11 | -0.01 |
| Normalized Basic EPS | 0.28 | 0.25 | 0.20 | 0.12 | 0.07 |
| EPS Diluted | 0.77 | 0.41 | 0.33 | 0.11 | -0.02 |
| Normalized Diluted EPS | 0.27 | 0.24 | 0.19 | 0.11 | 0.06 |
| Average Basic Shares Outstanding | 269.11M | 267.74M | 266.45M | 264.89M | 263.22M |
| Average Diluted Shares Outstanding | 278.95M | 276.64M | 272.64M | 268.84M | 265.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |